IRIS
SALA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.417
AS - Asia 2.350
EU - Europa 1.907
SA - Sud America 300
AF - Africa 56
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.034
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.343
SG - Singapore 1.147
IT - Italia 545
CN - Cina 502
VN - Vietnam 312
IE - Irlanda 300
BR - Brasile 250
RU - Federazione Russa 235
SE - Svezia 196
DE - Germania 136
IN - India 92
GB - Regno Unito 91
UA - Ucraina 91
TR - Turchia 77
FR - Francia 75
FI - Finlandia 62
HK - Hong Kong 59
CA - Canada 41
PL - Polonia 31
AT - Austria 26
JP - Giappone 25
ZA - Sudafrica 25
BD - Bangladesh 22
NL - Olanda 22
AR - Argentina 21
BE - Belgio 20
IQ - Iraq 18
MX - Messico 17
ES - Italia 15
CZ - Repubblica Ceca 12
KR - Corea 11
AE - Emirati Arabi Uniti 10
EG - Egitto 10
MY - Malesia 10
PK - Pakistan 10
EC - Ecuador 9
UZ - Uzbekistan 9
JO - Giordania 8
LT - Lituania 8
CH - Svizzera 7
GR - Grecia 7
MA - Marocco 6
PY - Paraguay 5
DZ - Algeria 4
IL - Israele 4
JM - Giamaica 4
LK - Sri Lanka 4
RS - Serbia 4
TN - Tunisia 4
UY - Uruguay 4
VE - Venezuela 4
AZ - Azerbaigian 3
BG - Bulgaria 3
DK - Danimarca 3
HR - Croazia 3
ID - Indonesia 3
KE - Kenya 3
NI - Nicaragua 3
PH - Filippine 3
TW - Taiwan 3
AL - Albania 2
AU - Australia 2
BB - Barbados 2
CL - Cile 2
CO - Colombia 2
HU - Ungheria 2
IR - Iran 2
LB - Libano 2
MD - Moldavia 2
PE - Perù 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
Totale 8.030
Salva come PNG Salva come JPEG
Città #
Singapore 864
Chandler 411
San Jose 388
Ashburn 309
Dublin 297
Dallas 205
Jacksonville 178
Beijing 168
Princeton 114
The Dalles 108
Santa Clara 103
Los Angeles 99
Ho Chi Minh City 89
Ann Arbor 85
Chieti 76
New York 65
Pescara 62
Hanoi 57
Altamura 52
Hong Kong 52
Boardman 48
Munich 48
Nanjing 48
Dearborn 44
Council Bluffs 40
Izmir 36
Dong Ket 35
Buffalo 34
Wilmington 34
Orem 30
Moscow 29
Warsaw 27
Redondo Beach 26
Montreal 25
Rome 24
Denver 23
Tongling 23
Frankfurt am Main 22
Hefei 22
Houston 22
Southend 22
São Paulo 22
Tokyo 22
Lappeenranta 21
Brussels 20
Da Nang 19
Johannesburg 19
Turku 19
Atlanta 18
Seattle 18
Washington 18
Brooklyn 17
Cambridge 16
Stockholm 16
Phoenix 15
Chennai 14
Milan 14
Nuremberg 14
Haiphong 13
Nanchang 13
Poplar 13
Pune 13
Collecorvino 12
Helsinki 12
London 12
Chicago 11
Hebei 11
L’Aquila 11
Mcallen 10
Norwalk 10
Seoul 10
Vienna 10
Woodbridge 10
Manchester 9
Mumbai 9
Ninh Bình 9
Rio de Janeiro 9
San Francisco 9
Tashkent 9
Mexico City 8
Montesilvano 8
Shenyang 8
Baghdad 7
Belo Horizonte 7
Boston 7
Castignano 7
Falls Church 7
Petaling Jaya 7
Shanghai 7
Zhengzhou 7
Amman 6
Amsterdam 6
Brasília 6
Brno 6
Campinas 6
Dubai 6
Fairfield 6
Hải Dương 6
Kunming 6
Tianjin 6
Totale 5.111
Salva come PNG Salva come JPEG
Nome #
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance 215
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 177
Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines 176
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 171
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages 163
ABCC3 is a novel target for the treatment of pancreatic cancer 161
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 158
ERBB3 BINDING ANTIBODY 152
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer 152
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer 150
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 149
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 149
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 149
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 147
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 147
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer 146
Humanized anti-bag3 antibodies 139
CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs–Letter 138
Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer 133
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma 132
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 132
Therapeutic efficacy of the novel stimuli-sensitive nano-ferritins containing doxorubicin in a head and neck cancer model 131
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 129
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 129
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration 129
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools 126
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 124
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 120
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 115
Breast cancer in the era of integrating "Omics" approaches 114
Antibody-drug conjugates: The new frontier of chemotherapy 110
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies 109
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 109
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 109
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 108
Phospholipase Cgamma1 is required for metastasis development and progression 108
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine 108
Engineered human nanoferritin bearing the drug genz-644282 for cancer therapy 108
The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1 107
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 105
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 105
The E27 β2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males 105
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 101
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines 100
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 100
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 97
The role of phosphoinositide 3-kinase C2α in insulin signaling 97
The role of phospholipase Cγ1 in breast cancer and its clinical significance 97
HER-3: Hub for escape mechanisms 95
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth 94
Endosialin-binding antibody 92
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 90
Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control 89
Feedback inhibition by RALT controls signal output by the ErbB network 87
A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation 85
Human head and neck cancer cell lines response to cold atmospheric plasma activated media is affected by the chemistry of culture media 84
MYC regulates metabolism through vesicular transfer of glycolytic kinases 84
Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling 83
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin 82
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate 81
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers 79
P63 role in breast cancer 78
Negative regulation of receptor tyrosine kinase signals 78
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET 77
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma 77
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma 72
Evaluation of Antibody-Drug Conjugate Performances Using a Novel HPLC-DAD Method for Tumor-Specific Detection of DM4 and S-Methyl-DM4 71
Role of BAG3 in cancer progression: A therapeutic opportunity 69
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy 68
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 68
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target 61
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review 60
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans 57
Galectin-3-binding protein is a risk factor for Diabetes, Metabolic Syndrome, and Inflammation. Cross-sectional and Longitudinal Results from the InCHIANTI study 51
New analytical challenges in characterization of Antibody-Drug Conjugates 44
Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker 35
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 28
BAG3 in human tumors 21
null 20
null 6
Totale 8.402
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.064
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202190 0 0 0 0 0 0 0 0 0 34 9 47
2021/2022333 15 2 5 62 18 12 13 23 29 20 28 106
2022/20231.065 94 175 71 124 92 176 49 89 129 12 38 16
2023/2024638 38 15 64 33 36 214 97 26 5 25 13 72
2024/20251.657 60 301 242 66 45 74 71 74 218 130 228 148
2025/20263.481 284 134 372 450 422 238 718 207 371 285 0 0
Totale 8.402